Share ownership Lupin Limited

500257

INE326A01037

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:56 05/06/2026 BST			5-day change	1st Jan Change
2,268.10 ^INR	+0.86%		-0.19%	+7.39%

06-05	Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments	MT
06-04	Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection	CI

Share class: Lupin Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	457,232,536	242,217,662 ( 52.97 %)	0	52.97 %

Major shareholders: Lupin Limited

Name	Equities	%	Valuation
Lupin Investments Pvt Ltd. 45.32 %	207,194,390	45.32 %	5 029 M ₹
HDFC Asset Management Co. Ltd. (Invt Mgmt) 4.281 %	19,571,242	4.281 %	475 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt) 2.719 %	12,430,693	2.719 %	302 M ₹
SBI Funds Management Ltd. (Investment Management) 2.131 %	9,741,995	2.131 %	236 M ₹
Mirae Asset Investment Managers (India) Pvt Ltd. 1.796 %	8,211,734	1.796 %	199 M ₹
HDFC Life Insurance Co. Ltd. (Investment Portfolio) 1.678 %	7,673,351	1.678 %	186 M ₹
SBI Life Insurance Co. Ltd. (Investment Portfolio) 0.8876 %	4,057,968	0.8876 %	98 M ₹
Manju Deshbandhu Gupta 0.8467 %	3,871,162	0.8467 %	94 M ₹
UTI Pension Fund Ltd. 0.738 %	3,373,980	0.738 %	82 M ₹
HSBC Asset Management (India) Pvt Ltd. 0.6137 %	2,805,707	0.6137 %	68 M ₹
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Others	45.32%
Institutional	20.37%
Individuals	1.53%
Governments	0.18%
Unknown	32.59%

Based on 1000 largest holdings

Geographical origin of shareholders

British Virgin Islands	45.33%
India	19.58%
Individuals	1.53%
Sweden	0.42%
United Kingdom	0.26%
Taiwan	0.07%
Singapore	0.05%
Ireland	0.04%
Netherlands	0.03%
Finland	0.02%
Brazil	0.01%
United States	0.01%
Luxembourg	0.01%
Malaysia	0.01%
Japan	0.01%
New Zealand	0.01%
Denmark	0.01%

Based on 1000 largest holdings

Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).

Employees

24,006

Sector

Pharmaceuticals

More about the company